¿µ³² ³»°ú°è ½ÅÀÌ½Ä ¿¬±¸È¸ Á¦25Â÷ ÇмúÁý´ãȸ : 2022-11-12±³À°ÀÏÀÚ : 2022-11-12
±³À°Àå¼Ò : °í½Å´ëÇб³ º¹À½º´¿ø 6µ¿5Ãþ ´ë°´ç
±³À°ÁÖÁ¦ :
¿µ³² ³»°ú°è ½ÅÀÌ½Ä ¿¬±¸È¸ Á¦25Â÷ ÇмúÁý´ãȸÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¿µ³²³»°ú°è½ÅÀÌ½Ä ¿¬±¸È¸
´ã´çÀÚ : ½ÅÈ£½Ä
¿¬¶ôó : 02-3486-8736
À̸ÞÀÏ :
67920@naver.com ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 90¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
ºÎ»ê±¤¿ª½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-12 ´ë°´ç 15:00~15:25 Next Generation Sequencing in Kidney Transplantation ¿øµ¿ÀÏ(°æºÏ´ëÇб³º´¿ø Áø´Ü°Ë»çÀÇÇаú)
±³À°½Ã°£ 11-12 ´ë°´ç 15:25~15:50 Complement-Mediated Renal Diseases after Kidney Transplantation: Current Diagnostic and Therapeutic Options °¼®ÈÖ(¿µ³²´ëÇб³º´¿ø ½ÅÀå³»°ú)
±³À°½Ã°£ 11-12 ´ë°´ç 15:50~16:15 Kidney Transplantation in HIV-Positive Individuals: Opportunities and Challenges ±èÀÏ¿µ(¾ç»êºÎ»ê´ëÇб³º´¿ø ½ÅÀå³»°ú)
±³À°½Ã°£ 11-12 ´ë°´ç 16:15~16:40 Frailty and Peritransplant Outcomes in Kidney Transplantation ¼Õ½ÂÇö(BHS ÇѼº´¿ø ½ÅÀå³»°ú)
ÈÞ½Ä 11-12 16:40~17:00 Break ()
±³À°½Ã°£ 11-12 ´ë°´ç 17:00~17:20 Case 1: BK nephropathy and urinary tract cancer ¹Ú»óµ·(°æºÏ´ëÇб³º´¿ø ½ÅÀå³»°ú)
±³À°½Ã°£ 11-12 ´ë°´ç 17:20~17:40 Case 2: Graft kidneyÀÇ pyelonephritis Áõ·Ê ±èº´¿ì(ÀÎÁ¦´ëÇб³ ºÎ»ê¹éº´¿ø ½ÅÀå³»°ú)
±³À°½Ã°£ 11-12 ´ë°´ç 17:40~18:00 Case 3: AMR(Amrubicin)°ú ¾àÁ¦Åõ¿© Áõ·Ê ±ÇÁßÇå(°è¸í´ëÇб³ µ¿»êº´¿ø ½ÅÀå³»°ú)
±³À°½Ã°£ 11-12 ´ë°´ç 18:00~18:20 Case 4: infection & De Novo FSGS(Focal segmental glomerulosclerosis) Áõ·Ê ±è´Ù¿î(ºÎ»ê´ëÇб³º´¿ø ½ÅÀå³»°ú)